Dicerna Pharmaceuticals Inc. went on the hunt for partners after refocusing its research and development efforts on its GalXC platform and soon began talking with Eli Lilly & Co. about harnessing the RNAi technology in the big pharma's areas of expertise. Now, the companies have entered into a formal collaboration agreement worth $200m up front and $3.5bn or more in milestone fees.
Cambridge, Mass.-based Dicerna and Lilly announced on Oct. 29 that they will use the GalXC platform to discover, develop and...








